Skip to content

Clinical trial for the efficacy of CJ_AJ on blood circulation

8 weeks, single-center, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of Citrus junos Siebold ex Tanaka extract on inhibition of platelet aggregation and blood circulation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0001031
Enrollment
42
Registered
2014-03-18
Start date
2014-03-11
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Oral administration of CJ_AJ (Citrus junos Siebold ex Tanaka extract 500 mg/day) or placebo, once daily for eight weeks

Sponsors

Ajou University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1) Male adult smokers more than 10 cigarettes per day 2) Platelet eggregation results > 70% at screening 3) Wiling to provide own written informed consent to trial participation

Exclusion criteria

Exclusion criteria: 1) Intake of any prescription drug for myocardial infarction, angina or bleeding disorders 2) Intake of aspirin, anti-coagulants or anti-platelet agents within 2 weeks prior to screening 3) Intake of red ginseng, ginseng, fermented bean paste within 2 weeks prior to screening 4) Uncontrolled hypertension (systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg) 5) Uncontrolled diabetes mellitus (fasting glucose > 180mg/dl, or intake of hypoglycemic agents within 3 months prior to screening) 6) Uncontrolled thyroid diseases 7) Surgery under general anesthesia within 3 months prior to screening 8) Serum creatinine > 2 x upper normal limit 9) Serum alanine Transaminase, aspartate Transaminase > 3 x upper normal limit 10) Subject with severe epigastric soreness or indigestion 11) Participation of other clinical study within 3 months prior to screening 12) Ineligible for study participation due to other reasons, according to the investigator’s judgment

Design outcomes

Primary

MeasureTime frame
Platelet aggregation test

Secondary

MeasureTime frame
Serotonin;Thromboxane B2;C-reactive protein;Coagulation tests;Lipid panel

Countries

Korea, Republic of

Contacts

Public ContactDOO-YEOUN CHO

Ajou University Hospital

dooycho@ajou.ac.kr+82-31-219-4271

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026